PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Gemfibrozil - Lipid modification

PAD Profile : Gemfibrozil - Lipid modification

Keywords :
Fibrates, high cholesterol, raised cholesterol, lipid lowering, hyperlipidaemia, FH, raised triglycerides, familial hypercholesterolaemia, hypertriglyceridaemia, lipid regulating
Brand Names Include :
Lopid

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Important
Formulations :
  • Capsules
  • Tablets
Important Information :
Not for initiation in new patients.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 March 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends the use of fibrates for lipid modification as follows:

Familial hypercholesterolaemia - as per NICE CG71 (updated July 2016) in patients with familial hypercholesterolaemia (FH) with intolerance or contraindications to statins or ezetimibe. Patients should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid or a fibrate to reduce their LDL-C concentration. For these patients, fibrates should be considered BLUE (no information sheet) on the traffic light system. Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

Hypertriglyceridaemia - as a treatment option for patients with hypertriglyceridaemia (>10mmol/L).
BLUE traffic light status - Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

Policy statements and further information below.

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More